The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Liver disease associated with canalicular transport defects: Current and future therapies
Open accessAbstract
Bile formation at the canalicular membrane is a delicate process. This is illustrated by inherited liver diseases due to mutations in ATP8B1, ABCB11, ABCB4, ABCC2 and ABCG5/8, all encoding hepatocanalicular transporters. Effective treatment of these canalicular transport defects is a clinical and scientific challenge that is still ongoing. Current evidence indicates that ursodeoxycholic acid (UDCA) can be effective in selected patients with PFIC3 (ABCB4 deficiency), while rifampicin reduces pruritus in patients with PFIC1 (ATP8B1 deficiency) and PFIC2 (ABCB11 deficiency), and might abort cholestatic episodes in BRIC (mild ATP8B1 or ABCB11 deficiency). Cholestyramine is essential in the treatment of sitosterolemia (ABCG5/8 deficiency). Most patients with PFIC1 and PFIC2 will benefit from partial biliary drainage. Nevertheless liver transplantation is needed in a substantial proportion of these patients, as it is in PFIC3 patients. New developments in the treatment of canalicular transport defects by using nuclear receptors as a target, enhancing the expression of the mutated transporter protein by employing chaperones, or by mutation specific therapy show substantial promise. This review will focus on the therapy that is currently available as well as on those developments that are likely to influence clinical practice in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“Some of the early trials in humans resulted in mortality and enthusiasm for this approach decreased [180].”
BackgroundEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Kast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., Tontonoz, P., Kliewer, S., Willson, T. M., & Edwards, P. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109326200 · Cited by 916
Paumgartner, G., & Beuers, U. (2002) · Hepatology · doi:10.1053/jhep.2002.36088 · Cited by 748 · cited 1×
“UDCA The main therapeutic target of UDCA is the protection of hepatocytes and cholangiocytes by replacing endogenous, cytotoxic bile salts [94,95].”
BackgroundDe Vree, J. M. L., Ottenhoff, R., Bosma, P. J., Smith, A. J., Aten, J., & Oude Elferink, R. P. J. (2000) · Gastroenterology · doi:10.1053/gast.2000.20222 · Cited by 186
The 'forgotten' bile acid sequestrants: is now a good time to remember?
Bays, H. E., & Goldberg, R. B. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31815a69fc · Cited by 83
Cited by
Progressive familial intrahepatic cholestasis
Davit-Spraul, A., Gonzales, E., Baussan, C., & Jacquemin, E. (2009) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-4-1 · Cited by 482
Pathogenesis of cholestatic liver disease and therapeutic approaches
Hirschfield, G. M., Heathcote, E. J., & Gershwin, M. E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.004 · Cited by 287
Mechanisms of drug-induced liver injury: from bedside to bench
Tujios, S., & Fontana, R. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.22 · Cited by 277
Progressive Familial Intrahepatic Cholestasis
Srivastava, A. (2014) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2013.10.005 · Cited by 268
Liu, X. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-7647-4_2 · Cited by 254
Metadata
- Authors
- Stapelbroek, J. M., van Erpecum, K. J., Klomp, L. W. J., & Houwen, R. H. J.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 52
- Issue
- 2
- Pages
- 258-271
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1965779979
- Cited by
- 179
- References
- 6
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liver disease associated with canalicular transport defects: Current and future therapies. https://app.cochat.ai/papers/10.1016/j.jhep.2009.11.012
- The paper
- Stapelbroek, J. M., van Erpecum, K. J., Klomp, L. W. J., & Houwen, R. H. J. (2010). Liver disease associated with canalicular transport defects: Current and future therapies. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2009.11.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.